AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25

AbbVie Inc.

2023-FY EPS reported $2.72 revenue$54,318,000,000

Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).
Q4 2023 GAAP EPS $0.46 (-66.7%); adjusted EPS $2.79 (-22.5%); revenue $14.3B (-5.4%).
Humira Q4 revenue $3.3B (-40.8% on biosimilar competition); Skyrizi up 51.9%; Rinvoq up 62.9%.
Announced ImmunoGen acquisition (~$10.1B equity) and Cerevel (~$8.7B); expected close mid-2024.
FY2024 adj. EPS guidance $11.05-$11.25 includes $0.32 dilution from pending deals; long-term CAGR reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbbVie Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $14.301 billion, EPS $2.79. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $14.301 billion
EPS: $2.79
Guidance: reaffirmed
Result: reported results

Exact text from the filing

These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense • Delivers Fourth-Quarter Net Revenues of $14.301 Billion, a Decrease of 5.4 Percent • Announced Definitive Transaction Agreements to Acquire ImmunoGen and Cerevel Therapeutics, Strengthening AbbVie’s Oncology and Neuroscience

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.